Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MLYS Stock Forecast 2026-2027
$30.58
Current Price
$2.52B
Market Cap
Buy 8
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to MLYS Price Targets
+83.1%
To High Target of $56.00
+68.4%
To Median Target of $51.50
-1.9%
To Low Target of $30.00
MLYS Price Momentum
+12.6%
1 Week Change
+27.0%
1 Month Change
+129.1%
1 Year Change
-15.7%
Year-to-Date Change
-35.8%
From 52W High of $47.65
+142.9%
From 52W Low of $12.59
📊 TOP ANALYST CALLS
Did MLYS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Mineralys is one of their latest high-conviction picks.
Latest MLYS Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, MLYS has a bullish consensus with a median price target of $51.50 (ranging from $30.00 to $56.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $30.58, the median forecast implies a 68.4% upside. This outlook is supported by 8 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matthew Caufield at HC Wainwright & Co., projecting a 83.1% upside. Conversely, the most conservative target is provided by Matthew Caufield at HC Wainwright & Co., suggesting a 1.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MLYS Analyst Ratings
8
Buy
1
Hold
0
Sell
MLYS Price Target Range
Low
$30.00
Average
$51.50
High
$56.00
Current: $30.58
Latest MLYS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MLYS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2026 | B of A Securities | Greg Harrison | Buy | Maintains | $51.00 |
| Dec 19, 2025 | Stifel | Annabel Samimy | Buy | Maintains | $52.00 |
| Nov 12, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $56.00 |
| Nov 11, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $55.00 |
| Oct 30, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $52.00 |
| Sep 11, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $50.00 |
| Sep 9, 2025 | Goldman Sachs | Richard Law | Buy | Maintains | $52.00 |
| Sep 8, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $42.00 |
| Sep 3, 2025 | Jefferies | Dennis Ding | Hold | Maintains | $26.00 |
| Aug 28, 2025 | B of A Securities | Greg Harrison | Buy | Maintains | $43.00 |
| Aug 13, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $42.00 |
| Jun 17, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $42.00 |
| Jun 11, 2025 | Jefferies | Dennis Ding | Hold | Initiates | $15.00 |
| May 13, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $42.00 |
| Apr 2, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $42.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $30.00 |
| Feb 24, 2025 | Guggenheim | Seamus Fernandez | Buy | Reiterates | $N/A |
| Feb 13, 2025 | Goldman Sachs | Richard Law | Buy | Maintains | $24.00 |
| Feb 13, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $30.00 |
| Nov 12, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $30.00 |
Mineralys Therapeutics, Inc. (MLYS) Competitors
The following stocks are similar to Mineralys based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Mineralys Therapeutics, Inc. (MLYS) Financial Data
Valuation Metrics
Market Cap
$2.52B
Enterprise Value
$1.86B
P/E Ratio
N/A
PEG Ratio
-16.7x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+26.1%
Current Ratio
43.8x
Debt/Equity
0.0x
ROE
-36.9%
ROA
-24.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Mineralys Therapeutics, Inc. (MLYS) Business Model
About Mineralys Therapeutics, Inc.
What They Do
Develops targeted therapies for cardio-renal-metabolic diseases.
Business Model
The company focuses on clinical-stage biopharmaceutical development, specifically targeting diseases linked to dysregulated aldosterone. It generates revenue through the advancement of its lead product candidate, lorundrostat, a selective aldosterone synthase inhibitor aimed at treating uncontrolled and resistant hypertension, addressing significant unmet medical needs.
Additional Information
Mineralys Therapeutics is supported by an experienced management team and expert advisors in cardiovascular and renal diseases. Founded in 2019 and based in Radnor, Pennsylvania, the company aims to innovate solutions for common cardiometabolic disorders that impact millions globally.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
76
CEO
Mr. Jon Congleton
Country
United States
IPO Year
2023
Website
mineralystx.comMineralys Therapeutics, Inc. (MLYS) Latest News & Analysis
Latest News
Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?
12 days ago
Quick Summary
CEO Jon Congleton sold 75,000 shares for ~$1.97 million on April 2, 2026, decreasing his direct ownership to 705,051 shares, a reduction of 9.61%.
Why It Matters
CEO Jon Congleton's sale of 75,000 shares may signal a lack of confidence in the company's near-term prospects, potentially impacting stock price and investor sentiment.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) appointed Jeffrey A. as a new executive, focusing on developing treatments for hypertension and related conditions.
Why It Matters
The appointment of Jeffrey A. may signal a strategic shift or enhanced leadership at Mineralys Therapeutics, potentially influencing future innovation and stock performance in a competitive biopharmaceutical market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mineralys Therapeutics, Inc. (MLYS) held its Q4 2025 earnings call, discussing financial performance and future outlook. Details on revenues and strategic plans were shared.
Why It Matters
Mineralys Therapeutics' Q4 2025 earnings call provides critical insights into financial performance, growth prospects, and strategic direction, impacting stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
1 month ago
Quick Summary
The FDA accepted the NDA for lorundrostat for adults with hypertension, with a PDUFA target date of December 22, 2026. A conference call is scheduled for today at 4:30 p.m. ET.
Why It Matters
FDA acceptance of lorundrostat's NDA signals potential market approval, impacting the company's valuation and future revenue. The PDUFA date creates a timeline for investment strategy adjustments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) will report its Q4 and full-year 2025 financial results on March 12, 2026, after market close. The company focuses on hypertension and related diseases.
Why It Matters
Mineralys Therapeutics' upcoming financial results could impact stock performance, reflecting the company's progress and market potential in treating hypertension and related conditions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The FDA has set a PDUFA date of December 22, 2026, for Mineralys Therapeutics' lorundrostat NDA, showing positive safety and blood pressure reduction data for hypertension treatment.
Why It Matters
The FDA's acceptance of Mineralys Therapeutics' NDA for lorundrostat signals potential market entry for a new hypertension treatment, which could drive future revenue and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MLYS Stock
What is Mineralys Therapeutics, Inc.'s (MLYS) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Mineralys Therapeutics, Inc. (MLYS) has a median price target of $51.50. The highest price target is $56.00 and the lowest is $30.00.
Is MLYS stock a good investment in 2026?
According to current analyst ratings, MLYS has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $30.58. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MLYS stock?
Wall Street analysts predict MLYS stock could reach $51.50 in the next 12 months. This represents a 68.4% increase from the current price of $30.58. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Mineralys Therapeutics, Inc.'s business model?
The company focuses on clinical-stage biopharmaceutical development, specifically targeting diseases linked to dysregulated aldosterone. It generates revenue through the advancement of its lead product candidate, lorundrostat, a selective aldosterone synthase inhibitor aimed at treating uncontrolled and resistant hypertension, addressing significant unmet medical needs.
What is the highest forecasted price for MLYS Mineralys Therapeutics, Inc.?
The highest price target for MLYS is $56.00 from Matthew Caufield at HC Wainwright & Co., which represents a 83.1% increase from the current price of $30.58.
What is the lowest forecasted price for MLYS Mineralys Therapeutics, Inc.?
The lowest price target for MLYS is $30.00 from Matthew Caufield at HC Wainwright & Co., which represents a -1.9% decrease from the current price of $30.58.
What is the overall MLYS consensus from analysts for Mineralys Therapeutics, Inc.?
The overall analyst consensus for MLYS is bullish. Out of 8 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $51.50.
How accurate are MLYS stock price projections?
Stock price projections, including those for Mineralys Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 3:22 AM UTC